Results of Operations and Financial Condition. On August 11, 2026 USA ET (August 12, 2026 AEST), Anteris Technologies Global Corp. (the “Company”) (i) filed the Form 10-Q for the quarter ended June 30, 2026 with a cover page (the “Results Announcement”) with the Australian Securities Exchange (“ASX”); and (ii) issued an ASX Announcement regarding the Company’s financial results for the quarter ended June 30, 2026, both of which include unaudited and other historical financial information for…

Entry into a Material Definitive Agreement. On May 22, 2026, Anteris Technologies Global Corp. (the “Company”) entered into a Sales Agreement (the “Agreement”) with TD Securities (USA) LLC (“TD Cowen”). Pursuant to the terms of the Agreement, the Company may offer and sell through TD Cowen, from time to time and at its sole discretion, shares of the Company’s common stock, par value of $0.0001 per share (the “Common Stock”), having an aggregate offering price of up to $250,000,000 (the “Offer…

Director — Ms. Susan Knight and Mr. Stephen Denaro: Appointment of Ms. Susan Knight and Mr. Stephen Denaro to the Board of Directors.

Results of Operations and Financial Condition. On May 12, 2026 USA ET (May 13, 2026 AEST), Anteris Technologies Global Corp. (the “Company”) (i) filed the Form 10-Q for the quarter ended March 31, 2026 with a cover page (the “Results Announcement”) with the Australian Securities Exchange (“ASX”); and (ii) issued an ASX Announcement regarding the Company’s financial results for the quarter ended March 31, 2026, both of which include unaudited and other historical financial information for the…

Termination of a Material Definitive Agreement. On April 28 , 2026, Anteris Technologies Global Corp., through its wholly owned subsidiary, Anteris Technologies Corporation (the “Company”), notified v2vmedtech, inc. (“v2v”) of its election to discontinue additional development contributions under the Contribution and Stock Purchase Agreement dated April 18, 2023 (the “Agreement”). The Company’s election occurred following completion of Stage 1 and during Stage 2 of the development program con…

Entry into a Material Definitive Agreement. Lease Agreement On April 23 , 2026, Anteris Technologies Global Corp., through its wholly owned subsidiary, Anteris Technologies Corporation (the “Company”), entered into a lease agreement (the “Lease”) with Northcross West Industrial Owner, LLC (“Northcross”) for approximately 181,436 square feet of space in an office and warehouse facility located in Brooklyn Park, Minnesota. The Lease has an initial term commencing September 1, 2026 and expiring…

Chief Financial Officer — Matthew McDonnell: Grant of supplemental RSUs to the Chief Financial Officer as a special award.

Results of Operations and Financial Condition. On February 26, 2026 USA ET (February 27, 2026 AEST), Anteris Technologies Global Corp. (the “Company”) (i) filed the Form 10-K for the fiscal year ended December 31, 2025 with a cover page (the “Results Announcement”) with the Australian Securities Exchange (“ASX”); and (ii) issued an ASX Announcement regarding the Company’s financial results for the fiscal year ended December 31, 2025, both of which include audited and other historical financia…

The issuance and sale of the PIPE Shares pursuant to the Purchase Agreement was made in reliance on the exemption from registration requirements provided by Section 4(a)(2) under the Securities Act. Forward-Looking Statements This current report contains forward-looking statements. Forward-looking statements include all statements that are not historical facts. Forward-looking statements generally are identified by the words “believe,” “project,” “expect,” “anticipate,” “estimate,” “intend,”…

Entry into a Material Definitive Agreement. Underwritten Offering On January 20, 2026, Anteris Technologies Global Corp. (the “Company”) entered into an Underwriting Agreement (the “Underwriting Agreement”) with Barclays Capital Inc., Wells Fargo Securities, LLC and Cantor Fitzgerald & Co., acting as representatives of the several underwriters named therein (the “Underwriters”), pursuant to which the Company agreed to issue and sell (the “Offering”) 34,782,609 shares (the “Firm Stock”) of the…

Director — Mr. Stephen Denaro: Mr. Stephen Denaro resigned from the Board of Directors and as a Class II director.

Termination of a Material Definitive Agreement . On November 26, 2025, Anteris Technologies Global Corp. (the “Company”) notified 4C Medical Technologies, Inc. (“4C”) that it was not renewing the Second Amended and Restated Supply and License Agreement, as amended (the “Supply Agreement”), between the Company and 4C, which provided for the supply by the Company to 4C of ADAPT ® tissue used in 4C’s production of medical devices related to transcatheter mitral valve and tricuspid valve regurgit…

Results of Operations and Financial Condition. On November 12, 2025 USA ET (November 13, 2025 AEST), Anteris Technologies Global Corp. (the “Company”) (i) filed the Form 10-Q for the quarter ended September 30, 2025 with a cover page (the “Results Announcement”) with the Australian Securities Exchange (“ASX”); and (ii) issued an ASX Announcement regarding the Company’s financial results for the quarter ended September 30, 2025, both of which include unaudited and other historical financial in…

Unregistered Sales of Equity Securities. The information contained in

Unregistered Sales of Equity Securities. On or about October 23, 2025 (October 24, 2025 AEST), Anteris Technologies Global Corp. (the “Company”) entered into (i) subscription agreements (the “Subscription Agreements”) with certain investors, pursuant to which we agreed to sell 2,244,896 shares (the “Shares”) of the Company’s common stock, par value $0.0001 per share (“Common Stock”), and accompanying five-year warrants (the “Common Stock Warrants”) to purchase 2,244,896 shares of Common Stock…

Results of Operations and Financial Condition. On August 11, 2025 USA ET (August 12, 2025 AEST), Anteris Technologies Global Corp. (the “Company”) (i) lodged the Form 10-Q for the quarter ended June 30, 2025 with a ‘Results for announcement to the market’ cover page (the “Results Announcement”) with the Australian Securities Exchange (“ASX”) and (ii) issued an ASX Announcement regarding the Company’s financial results for the quarter ended June 30, 2025, both of which include unaudited and ot…

Entry into a Material Definitive Agreement. On July 28 , 2025, Anteris Technologies Global Corp. (the “Company”) entered into the First Amended and Restated Master Services Agreement (the “A&R MSA”) with Switchback Medical, LLC (“Switchback”), pursuant to which Switchback provides various development and manufacturing services, including engineering and testing services, pursuant to purchase orders made by the Company from time to time, at set prices per unit, and in compliance with various q…

Director — Mr. David Roberts and Mr. Gregory Moss: Appointment of new directors to the Board.

Results of Operations and Financial Condition. On May 13, 2025 USA ET (May 14, 2025 AEST), Anteris Technologies Global Corp. (the “Company”) (i) lodged a financial report (the “ASX Quarterly Results Announcement”) with the Australian Securities Exchange (“ASX”) and (ii) issued an ASX Announcement regarding the Company’s financial results for the quarter ended March 31, 2025, both of which include unaudited and other historical financial information for the quarter ended March 31, 2025. The AS…

Results of Operations and Financial Condition. On March 12, 2025 USA ET (March 13, 2025 AEST), Anteris Technologies Global Corp. (the “Company”) (i) lodged a financial report (the “Results Announcement”) with the Australian Securities Exchange (“ASX”) and (ii) issued an ASX Announcement regarding the Company’s financial results for the fiscal year ended December 31, 2024, both of which include audited and other historical financial information for the fiscal year ended December 31, 2024. The…

President and Class II director — David St Denis: David St Denis was promoted to President and appointed as a Class II director.

Triggering Events that Accelerate or Increase a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement. As previously disclosed, on December 16, 2024, Anteris Technologies Global Corp. (the “Company”) completed its previously announced initial public offering (the “IPO”) of 14,800,000 shares of its common stock, par value $0.0001 per share (“Common Stock”). Prior to the consummation of the IPO, the Company completed a series of reorganization transactions (the “Re…

Director: The filing discloses the adoption of an equity incentive plan, the establishment of a staggered board structure, and the execution of standard employment agreements following a reorganization, rather than a specific executive departure or hire.

Unregistered Sales of Equity Securities. In connection with the Reorganization, on December 13, 2024, the Company issued (i) 21,139,816 shares of Common Stock to shareholders of ATL, 20,360,496 of which are represented by CDIs, pursuant to the Scheme and (ii) 6,117,807 options to purchase shares of Common Stock pursuant to the Option Scheme. The foregoing issuances were made pursuant to an exemption from registration under Section 3(a)(10) of the Securities Act. Each option is exercisable int…

Material Modification to Rights of Security Holders. The information set forth under